The use of gabapentin for the treatment of postherpetic neuralgia

Clinical Therapeutics

Volumn 25, Issue 3, 2003, Pages 852-889

  Singh, Devada ^a   Kennedy, Deborah H ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Gabapentin; Herpes zoster; Neuropathic pain; Pain; Pathophysiology; Pharmacokinetics; Postherpetic neuralgia

Indexed keywords

AMITRIPTYLINE; ANTACID AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CENTRAL DEPRESSANT AGENT; CORTICOSTEROID; DESIPRAMINE; DOXEPIN; GABAPENTIN; IMIPRAMINE; LEVOTHYROXINE SODIUM; LIDOCAINE; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PHENOTHIAZINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ATAXIA; BACKACHE; BLOOD DYSCRASIA; BODY WEIGHT DISORDER; BRADYCARDIA; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEART ARREST; HEMOPTYSIS; HERPES ZOSTER; HUMAN; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; MALE; NAUSEA; NEURALGIA; POSTHERPETIC NEURALGIA; RETINA BLOOD VESSEL OCCLUSION; SEDATION; SHOCK; SIDE EFFECT; SOMNOLENCE; TREMOR; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0037361930     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80111-X     Document Type: Article

References (100)

1. Dan K, Yokota T, Koyama N, et al. Mechanism-based treatment of zoster-associated pain. Pain Rev. 2000;7:157-180.
2. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340-346.
3. Arvin AM. Varicella-zoster virus: Overview and clinical manifestations. Semin Dermatol. 1996;15(Suppl 1):4-7.
4. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med. 1997;157:1217-1224.
5. Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis. 1998;178(Suppl 1):S71-S75.
6. Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32:1481-1486.
7. Dworkin RH, Perkins FM, Nagasako EM. Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. Clin J Pain. 2000;16(Suppl):S90-S100.
8. Bajwa ZH, Ho CC. Herpetic neuralgia: Use of combination therapy for pain relief in acute and chronic herpes zoster. Geriatrics. 2001;56:18-24.
9. Nagasako EM, Johnson RW, Griffin DR, Dworkin RH. Rash severity in herpes zoster: Correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol. 2002;46:834-839.
10. Baron R. Peripheral neuropathic pain: From mechanisms to symptoms. Clin J Pain. 2000;16(Suppl):S12-S20.
11. Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. Lancet. 1994;343:1648.
12. Gershon AA. Epidemiology and management of postherpetic neuralgia. Semin Dermatol. 1996;15(Suppl 1):8-13.
13. Vander Straten M, Carrasco D, Lee P, Tyring SK. Reduction of postherpetic neuralgia in herpes zoster. J Cutaneous Med Surg. 2001;5:409-416.
14. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32-42.
15. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605-1609.
16. Schmader K, George LK, Burchett BM, et al. Race and stress in the incidence of herpes zoster in older adults. J Am Geriatr Soc. 1998;46:973-977.
17. Haanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hyperesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage. 2000;20:50-58.
18. Mao J, Chen LL. Gabapentin in pain management. Anesth Analg. 2000;91:680-687.
19. Attal N. Chronic neuropathic pain: Mechanisms and treatment. Clin J Pain. 2000;16(Suppl):S118-S130.
20. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand. 2000;101:359-371.
21. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000;16(Suppl):S101-S105.
22. Zovirax® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
23. Acosta EP, Balfour HH Jr. Acyclovir for the treatment of postherpetic neuralgia: Efficacy and pharmacokinetics. Antimicrob Agents Chemother. 2001;45:2771-2774.
24. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896-900.
25. Valtrex® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2002.
26. Soul-Lawton J, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39:2759-2764.
27. Wang LH, Schultz M, Weller S, et al. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrob Agents Chemother. 1996;40:80-85.
28. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595-605.
29. De Bony F, Tod M, Bidault R, et al. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother. 2002;46:458-463.
30. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: Randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immuno-competent patients 50 years and older. Arch Fam Med. 2000;9:863-869.
31. Famvir® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002.
32. Filer CW, Allen GD, Brown TA, et al. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica. 1994;24:357-368.
33. Boike SC, Pue MA, Freed MI, et al. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol Ther. 1994;55:418-426.
34. Centers for Disease Control and Prevention (CDC). National Immunization Program. Varicella vaccine. Available at: http://www.cdc.gov/nip/vaccine/varicella/faqs-clinic-vaccine.htm. Accessed September 15, 2002.
35. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48(RR-6):1-5.
36. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to vancella boosts immunity to herpes zoster: Implications for mass vaccination against chickenpox. Vaccine. 2002;20:2500-2507.
37. Neurontin® [package insert]. Vega Baja, Puerto Rico: Parke-Davis Pharmaceuticals; 2002.
38. Lidoderm® [package insert]. Chadds Ford, Pa: Endo Pharmaceuticals Inc; 2000.
39. Tegretol® [package insert]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; 2002.
40. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995;37:246-253.
41. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: Double-blind controlled study of a new treatment method for postherpetic neuralgia. Pain. 1996;65:39-44.
42. Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988;38:1427-1432.
43. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 1990;47:305-312.
44. Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial. Neurology. 1998;51:1166-1171.
45. Furlanut M, Benetello P, Spina E. Pharmacokinetic optimisation of tncyclic antidepressant therapy. Clin Pharmacokinet. 1993;24:301-318.
46. Coudore F, Besson A, Eschalier A, et al. Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after one and six half-life repeated administrations to rats. Gen Pharmacol. 1996;27:215-219.
47. Ghahramani P, Ellis SW, Lennard MS, et al. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997;43:137-144.
48. Burch JE, Hullin RP. Amitriptyline pharmacokinetics. A crossover study with single doses of amitriptyline and nortriptyline. Psychopharmacology (Berl). 1981;74:35-42.
49. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit. 2001;23:435-440.
50. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1966;29:265-267.
51. Cotter LM, Eadie MJ, Hooper WD, et al. The pharmacokinetics of carbamazepine. Eur J Clin Pharmacol. 1977;12:451-456.
52. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Carbamazepine pharmacokinetics in obese and lean subjects. Ann Pharmacother. 1995;29:843-847.
53. Eichelbaum M, Ekbom K, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975;58:337-341.
54. Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol. 1999;39:1109-1125.
55. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet. 1996;31:198-214.
56. Nolen WA, Jansen GS, Broekman M. Measuring plasma levels of carbamazepine. A pharmacokinetic study in patients with affective disorders. Pharmacopsychiatry. 1988;21:252-254.
57. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol. 1994;47:355-360.
58. Vollmer KO, Anhut H, Thomann P, et al. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. Adv Epileptology. 1989;17:209-211.
59. Gidal BE, Maly MM, Kowalski JW, et al. Gabapentin absorption: Effect of mixing with foods of varying macronutrient composition. Ann Pharmacother. 1998;32:405-409.
60. Turck D, Vollmer KO, Bockbrader H, et al. Dose-linearity of the new anticonvulsant gabapentin after multiple oral doses. Eur J Clin Pharmacol. 1989;36(Suppl):A310. Abstract.
61. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276-281.
62. Haig GM, Bockbrader HN, Wesche DL, et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol. 2001;41:507-514.
63. Boyd RA, Turck D, Abel RB, et al. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia. 1999;40:474-479.
64. Graves NM, Leppik IE, Wagner ML, et al. Effect of gabapentin on carbamazepine levels. Epilepsia. 1990;31:644-645.
65. Uthman BM, Wilder BJ. Interaction between valproate (VPA) and gabapentin (GBP) in patients receiving VPA monotherapy. Epilepsia. 1989;30:701.
66. Hooper WD, Kavanagh MC, Herkes GK, Eadie MJ. Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin. Br J Clin Pharmacol. 1991;31:171-174.
67. Eldon MA, Underwood BA, Randinitis EJ, Sedman AJ. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology. 1998;50:1146-1148.
68. Busch JA, Radulovic LL, Bockbrader HN, et al. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy adults. Pharmacol Res. 1992;9(Suppl 10):S315.
69. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain. 2001;94:215-224.
70. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA. 1998;280:1837-1842.
71. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy Drugs. 2000;60:1029-1052.
72. Chong MS, Smith TE. Anticonvulsants for the management of pain. Pain Rev. 2000;7:129-149.
73. Jensen TS. Anticonvulsants in neuropathic pain: Rationale and clinical evidence. Eur J Pain. 2002;6(Suppl A):61-68.
74. Backonja M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain. 2000;16(Suppl):S67-S72.
75. Rose MA, Kam PC. Gabapentin: Pharmacology and its use in pain management. Anaesthesia. 2002;57:451-462.
76. Ben-Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. Epilepsy Res. 1992;11:45-49.
77. Ojemann LM, Friel PN, Ojemann GA. Gabapentin concentration in human brain. Epilepsia. 1988;29:694. Abstract.
78. Hengy H, Kolle EU. Determination of gabapentin in plasma and urine by high-performance liquid chromatography and pre-column labeling for ultraviolet detection. J Chromatogr. 1985;341:473-478.
79. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994;56:154-159.
80. Wong MO, Eldon MA, Keane WF, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol. 1995;35:622-626.
81. Wong JO, Tan TD, Leung PO, et al. Gabapentin for the management of intractable postherpetic neuralgia: Report of 4 cases. Pain Clinic. 2002;13:277-283.
82. Filadora VA 2nd, Sist TC, Lema MJ. Acute herpetic neuralgia and postherpetic neuralgia in the head and neck: Response to gabapentin in five cases. Reg Anesth Pain Med. 1999;24:170-174.
83. Merren MD. Gabapentin for treatment of pain and tremor: A large case series. South Med J. 1998;91:739-744.
84. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996;12:56-58.
85. Sist TC, Filadora VA 2nd, Miner M, Lema M. Experience with gabapentin for neuropathic pain in the head and neck: Report of ten cases. Reg Anesth. 1997;22:473-478.
86. Segal AZ, Rordorf G. Gabapentin as a novel treatment for postherpetic neuralgia. Neurology. 1996;46:1175-1176.
87. Farrar JT, Young JP Jr, LaMoreaux L, et al, Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
88. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
89. Rice AS, Maton S. Response to Comment on: Rice AS, Maton S. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo-controlled study. [Pain. 2001;94:215-224.] Pain. 2002;96:411-412.
90. Cook RJ, Sackett DL. The number needed to treat: A clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
91. Bowsher D. Comment on: Rice AS, Maton S. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. [Pain. 2001;94:215-224.] Pain. 2002;96:409-410.
92. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders. Clin Pharmacokinet. 1995;29:442-450.
93. Yukawa E. Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring. Clin Pharmacokinet. 1996;31:120-130.
94. Pisani F, Fazio A, Artesi C, et al. An epidemiological study of the clinical impact of pharmacokinetic anticonvulsant drug interactions based on serum drug level analysis. Ital J Neurol Sci. 1987;8:135-141.
95. Fischer JH, Barr AN, Rogers SL, et al. Lack of senous toxicity following gabapentin overdose. Neurology. 1994;44:982-983.
96. Neurontin (Pfizer U.S.P.G.) gabapentin. In: Drug Topics® Red Book®. Montvale, NJ: Thomson Medical Economics; 2002:453.
97. Amitriptyline (PD-RX Pharm). In: Drug Topics® Red Book®. Montvale, NJ: Thomson Medical Economics; 2002:197.
98. Desipramine (Eon). In: Drug Topics® Red Book®. Montvale, NJ: Thomson Medical Economics; 2002:296.
99. Nortriptyline (Southwood) gabapentin. In: Drug Topics® Red Book®. Montvale, NJ: Thomson Medical Economics; 2002:459.
100. Lidoderm 5% patch (Endo Labs) lidocaine. In: Drug Topics® Red Book®. Montvale, NJ: Thomson Medical Economics; 2002:407.